合格的损伤生物标志物在早期临床药物开发过程中表现出价值
Kodihalli C Ravindra1, Kelly A Fader2, David Potter3
1Department of Drug Safety Research and Development, Pfizer Inc., Groton, CT 06340, United States.
概括
这项研究表明,FDA合格的脏生物标志物小组在早期试验中有效地识别了药物诱导的损伤 (DIKI). 该小组帮助健康志愿者和患者群体对新疗法进行风险评估和临床决策.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 腎臟病學 (nephrology) 是一種醫學.
- 生物标志物发现发现
背景情况:
- 药物诱导损伤 (DIKI) 在药物开发和临床使用过程中存在重大风险.
- 早期发现DIKI对于患者的安全和治疗成功至关重要.
- 经过FDA认证的脏安全生物标志物面板为DIKI评估提供了一个有前途的方法.
研究的目的:
- 在第一期和第二期临床试验中实施和评估FDA合格的脏安全生物标志物小组.
- 评估生物标志物小组在检测新疗法 (PFE-1和PFE-2) 诱导的DIKI中的实用性.
- 为指导新药的风险评估,剂量选择和临床决策.
主要方法:
- 使用了六种尿路生物标记物的小组:集群素 (CLU),细胞素-C (CysC),损伤分子-1 (KIM-1),N-乙-β-d-葡萄糖胺酶 (NAG),中性纤维素凝酶相关的脂素 (NGAL) 和骨质素 (OPN).
- 从健康志愿者 (HVs) 和1期 (PFE-1) 和2期 (PFE-2) 试验中的患者以及狼患者和HVs的尿液样本中测量了生物标志物.
- 计算了FDA定义的复合测量 (CM) 作为六个生物标志物的几何平均响应.
主要成果:
- 在接受PFE-1的HV中,复合量 (CM) 增加了约30%,表明DIKI.
- 接受PFE-2的类风湿性关节炎患者的CM与安慰剂可比,在临床剂量下降了DIKI的风险.
- 与HV患者相比,RA和狼患者的CLU,KIM-1,NAG,NGAL和OPN都增加了.
结论:
- 美国食品和药物管理局合格的脏生物标志物小组在第一阶段试验中成功识别了DIKI.
- 该小组在第二阶段试验中帮助降低候选治疗药物 (PFE-2) 的风险,证明了其在临床决策中的价值.
- 这项研究验证了这种生物标志物小组在不同人群中评估新型治疗药物的安全性的使用.
相关概念视频
Factors Affecting Renal Clearance: Renal Impairment
74
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
74
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
134
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
134
Renal Failure: Dose Adjustments
79
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
79
Renal Drug Clearance: Comparison Between Renal Excretion Methods
117
Renal clearance is a critical parameter encompassing kidney filtration, secretion, and reabsorption processes. It is calculated using a specific equation to determine the rate at which the kidneys clear a drug.
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
117
Renal Drug Clearance: Overview
180
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
180


